Fibrosing mediastinitis
Conditions
Interventions
Experimental group:Ambesentan
Control group:Placebo
Sponsors
Gansu Provincial Peolie's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Right heart catheterization examination within 3 months before admission: mean pulmonary artery pressure >= 25 mmHg, pulmonary vascular resistance > 3 wood, pulmonary artery wedge pressure or left ventricular end diastolic pressure <= 15 mmHg; 2. Patients diagnosed as fibromediastinitis by CT pulmonary angiography; 3. Patients with baseline 6MWD between 150-450m; 4. WHO FC grade II or III patients; 5. The forced expiratory volume per second (FEV1) of patients with total vital capacity greater than or equal to 60% of the predicted normal value was greater than or equal to 55% of the predicted normal value; 6. Patients with good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients younger than 18 years old or over 75 years old; 2. Patients with moderate or severe valvular disease, pericardial constriction, restrictive or congestive cardiomyopathy, life-threatening arrhythmia, left ventricular ejection fraction 2 times ULN, serum bilirubin > 1.5 times ULN; 15. Patients with drug allergy or intolerable adverse reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walk distance;WHO functional classification; | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP; | — |
Countries
China
Contacts
Public ContactCao Yunshan
Gansu Provincial Hospital
Outcome results
None listed